These companies set to benefit from sales of Biogen med Leqembi


Radiologist in the control room performing an MRI scan

andresr/E+ via Getty Images

When the US FDA granted full approval of Biogen (NASDAQ:BIIB) and Eisai’s (OTCPK:ESAIY) Alzheimer’s treatment Leqembi (lecanemab), it was a boon to the two companies. It meant that the Centers for Medicare and Medicaid Services (

Source link

Leave A Reply

Your email address will not be published.